Koers Xenetic Biosciences Inc Nasdaq
Aandelen
US9840152063
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 2,13 mln. 2,67 mln. 2,48 mln. | Omzet 2025 * | 1,42 mln. 1,78 mln. 1,66 mln. | Marktkapitalisatie | 5,24 mln. 6,58 mln. 6,11 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -4 mln. -5,02 mln. -4,66 mln. | Nettowinst (verlies) 2025 * | -8 mln. -10,04 mln. -9,32 mln. | EV/omzet 2024 * | 2,46 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 3,69 x |
K/w-verhouding 2024 * |
-1,24
x | K/w-verhouding 2025 * |
-5,21
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 80,81% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 11-07-16 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 03-04-17 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 01-03-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 11-07-16 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 14-08-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+6,79% | 14,16 mld. | |
+38,61% | 12,63 mld. |